BioAge Labs, Inc. (BIOA)
Nasdaq: BIOA · Pharmaceutical Preparations · Emeryville, CA · filing with the SEC since 2024
Income statement, as filed
In thousands of US dollars (USD), as filed; per-share figures in US dollars; share counts. The fiscal year ends in December.| Fiscal year | FY 2025 | FY 2024 | FY 2023 |
|---|---|---|---|
| Period ending | Dec 31, 2025 | Dec 31, 2024 | Dec 31, 2023 |
| Report filed | Mar 24, 2026 | Mar 20, 2025 | · |
| Revenue | 8,995 | 0 | · |
| Research and development | 73,966 | 59,036 | 33,886 |
| General and administrative | 27,809 | 19,158 | 14,514 |
| Total operating expenses | 101,775 | 78,194 | 48,400 |
| Operating income | -92,780 | -78,194 | -48,400 |
| Interest expense | 697 | 2,367 | 7,794 |
| Total non-operating income (expense) | 12,175 | 7,085 | -15,454 |
| Income before income taxes | -80,605 | -71,109 | -63,854 |
| Income tax expense | 0 | 0 | 0 |
| Net income including non-controlling interests | -80,605 | -71,109 | -63,854 |
| Net income | -80,605 | -71,109 | -63,854 |
| Earnings per share, basic | -2.24 | -6.63 | -38.17 |
| Earnings per share, diluted | -2.24 | -6.63 | -38.17 |
| Weighted average shares, basic | 35,932,914 | 10,726,521 | 1,672,793 |
| Weighted average shares, diluted | 35,932,914 | 10,726,521 | 1,672,793 |
As filed with the SEC, each figure from the newest report that carries it, and linked to it. Nothing here is computed.A dot is a line not tagged for that period. r restated by the company in a later report; b a share figure put on the newest basis or filed in the wrong unit. Hover a figure for its filing and note.
What each line is, and the XBRL concept behind it
Revenue what customers paid for what it sold
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTaxResearch and development spent on inventing what it sells next
us-gaap:ResearchAndDevelopmentExpenseGeneral and administrative the cost of running the company itself
us-gaap:GeneralAndAdministrativeExpenseTotal operating expenses the running costs together
us-gaap:OperatingExpensesOperating income profit from running the business, before interest and tax
us-gaap:OperatingIncomeLossInterest expense what its borrowing cost
us-gaap:InterestExpenseNonoperatingTotal non-operating income (expense) everything outside the business, together
us-gaap:NonoperatingIncomeExpenseIncome before income taxes profit before tax
us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterestIncome tax expense tax charged on the period's profit
us-gaap:IncomeTaxExpenseBenefitNet income including non-controlling interests the whole group's profit, minority holders' share included
us-gaap:ProfitLossNet income the profit or loss that belongs to the company's shareholders
us-gaap:NetIncomeLossEarnings per share, basic net income per share outstanding
us-gaap:EarningsPerShareBasicEarnings per share, diluted net income per share, counting every share that could be issued
us-gaap:EarningsPerShareDilutedWeighted average shares, basic the average count of shares outstanding
us-gaap:WeightedAverageNumberOfSharesOutstandingBasicWeighted average shares, diluted the average count with every share that could be issued
us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding